PKA-IN-2 (Compound j1) is an inhibitor targeting the serine/threonine kinase J-PKAcalpha, with an IC50 of 6.3 nM. PKN-IN-1 is applicable for research on liver cancer, including fibrolamellar hepatocellular carcinoma.
Target:
PKA
* VAT and and shipping costs not included. Errors and price changes excepted